Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
24 October 2026 · filed under 48908dec8360
Tango Therapeutics reported Thursday that an experimental combination therapy produced tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, according to STAT News, which covered the data presented at ESMO 2026.
The combination pairs Tango’s vopimetostat with Revolution Medicines’ rasonque, STAT reported. Pancreatic cancer remains among the most difficult malignancies to treat, with few targeted options showing strong activity in advanced disease, and STAT’s coverage situates the reported response rate against that backdrop of limited existing options.
STAT’s report, published under its STAT+ subscription tier, did not specify in the material provided the trial’s full patient count, dosing details, or duration of response, details that would typically accompany a conference presentation of this kind. The bulletin’s source summary attributes the 82% figure directly to Tango’s own reporting of the trial results.
No additional outlets were cited alongside STAT News in the material reviewed for this item. Further details, including the trial’s design, patient population size, and any regulatory next steps Tango or Revolution Medicines may pursue, were not available in the provided summary. Readers seeking the complete dataset, including survival metrics and safety findings, should consult STAT’s full report or primary conference materials from ESMO 2026 directly.